Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
← catalyst calendarNCT06585410 · readout in 1,353 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
369estimated
Sites
52
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-02 | actual | When the study began enrolling |
| Primary completion | 2030-05-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-03 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
- Drug: Cemiplimab — also filed as Libtayo
- Procedure: Standard of care
Primary outcomes
what the primary-completion date above is the date OFEvent-Free Survival (EFS) as assessed by the investigator
measured Up to 1 year
EFS as assessed by the investigator
measured Up to 3 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed